da Luca Bonadei | Set 18, 2019 | Regulatory
https://www.globenewswire.com Ocugen, a biopharmaceutical company focused on discovering, developing and commercializing of innovative therapies that address rare and underserved eye diseases, has announced the U.S. FDA granted the second orphan drug designation for...
da Luca Bonadei | Set 18, 2019 | Regolatorio
https://www.globenewswire.com Ocugen, azienda biofarmaceutica focalizzata nella scoperta, sviluppo e commercializzazione di terapie innovative per il trattamento di rare patologie dell’occhio, ha annunciato la concessione da pate della FDA della designazione orfana...
da Luca Bonadei | Lug 18, 2019 | Clinical
https://www.globenewswire.com Apellis Pharmaceuticals, a biopharmaceutical company focused on the development of therapeutic compounds to treat disease through the control of the complement system, announced its plans to develop APL-9 for the prevention of complement...
da Luca Bonadei | Lug 18, 2019 | Clinica
https://www.globenewswire.com Apellis Pharmaceuticals, azienda biofarmaceutica focalizzata nello sviluppo di terapie per il trattamento di patologie legate al sistema del complemento, ha annunciato che avvirà il programma di sviluppo per APL-9, trattamento preventivo...
da Luca Bonadei | Lug 18, 2019 | Business
https://www.pharmastar.it Kite Pharma, part of Gilead Sciences, has announced that it will build a 6.000 square meters facility at its Oceanside, California, biologics site just for developing viral vectors, the tools needed to deliver genetic material into cells. So...